Recent Event

<>

October 18, 2017 - October 20, 2017

Cambridge

MIT Gene Therapy Design Lab

Speaker: Jane F. Barlow

Real Endpoints LLC

The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation “think and do tank” involving a range of stakeholders in the healthcare system, hosted a collaborative Design Lab to advance work on innovative financing models that could make potentially curative—but expensive—therapies accessible to patients and affordable to payers, while ensuring sustainable innovation by industry.

view event >

Recent Events

June 8, 2020 - June 12, 2020

Moderator: Jeffrey Berkowitz, CEO and Director

Real Endpoints

Real Endpoints is excited to be moderating this important panel on reimbursement of chronic rare and orphan disease therapies at the upcoming BIO International Digital Convention

view event >

May 19, 2020 12:00pm ET

Panelist: Jeffrey Berkowitz, CEO and Director
Roger Longman, Founder and Chairman

Real Endpoints

CELLO Health BioConsulting Webinar with Real Endpoints: In this senior executive webinar, we’ll give a boardroom presentation, and take your questions, on cancer’s unique payer situation and its stability — or instability. Our focus: how the informed biotech executive team manages early (and late) clinical and commercial development to ensure success not just with the FDA but in what may be a very different and less favorable reimbursement environment

view event >

May 4, 2020 12:30pm ET

HBO show!

Chief Clinical Officer: Jane F. Barlow, MD, MPH, MBA

Real Endpoints

Watch the replay of Real Endpoint’s Jane Barlow – joined by Congressman Scott Peters – speaking to the challenges of seeking reimbursement for cell and gene therapy during a time of upheaval.

view event >

October 16, 2019 - October 18, 2019

New York, NY

Speaker: Jeff Berkowitz
Roger Longman

Real Endpoints

Value-based pharma contracts have been rare in oncology relative to other therapeutic categories — and for a variety of good and bad reasons. But in the hyper-competitive future, risk-sharing will become a necessary component in every oncology company’s strategic toolkit. In five separate sessions at the value-based cancer summit in NY Oct 16-18, Real Endpoints CEO Jeff Berkowitz and Chairman Roger Longman will help lay out the challenges and the unexploited opportunities in oncology VBAs

view event >

October 13, 2019 - October 15, 2019

Laguna Beach, CA

Panel: Drug Pricing and Value Based Reimbursement

Jeff Berkowitz

Real Endpoints

Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors — about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.

October 2, 2019 1:15pm

San Diego, CA

Roger Longman

Real Endpoints

Real Endpoints Founder, Roger Longman, is looking forward to leading a robust discussion focused on solutions to creating access to cell and gene therapies — solutions that work for both payers and biopharma.

view event >